Browse FCGR1A

Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Note=Stabilized at the cell membrane through interaction with FCER1G.
Domain PF00047 Immunoglobulin domain
PF13895 Immunoglobulin domain
Function

High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006898 receptor-mediated endocytosis
GO:0006909 phagocytosis
GO:0006911 phagocytosis, engulfment
GO:0010324 membrane invagination
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0034341 response to interferon-gamma
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I
GO:0048002 antigen processing and presentation of peptide antigen
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0071346 cellular response to interferon-gamma
GO:0099024 plasma membrane invagination
Molecular Function GO:0005057 receptor signaling protein activity
GO:0019864 IgG binding
GO:0019865 immunoglobulin binding
Cellular Component GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0031901 early endosome membrane
GO:0044440 endosomal part
GO:0045334 clathrin-coated endocytic vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04380 Osteoclast differentiation
hsa04640 Hematopoietic cell lineage
hsa04666 Fc gamma R-mediated phagocytosis
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1236978: Cross-presentation of soluble exogenous antigens (endosomes)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2029481: FCGR activation
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-2029485: Role of phospholipids in phagocytosis
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCGR1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FCGR1A and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24523193Chronic Myelomonocytic Leukemia; Acute Myelomonocytic LeukemiaPromote immunityHere, we report the use of CD64 as a novel target for specific CMML and AMML therapy, and correlate CD64 expression with typical surface markers representing these diseases.
16452176MelanomaPromote immunity; increase the efficacy of immunotherapyThe high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. MPL did potently boost TA99 antibody-induced effects, and combination therapy was, again, found to be dependent on the presence of FcgammaRI.
29576376Pancreatic CarcinomaPromote immunityFc gamma receptor All mAb formats were strong agonists when hyper-crosslinked; however, only those binding the membrane-distal cysteine-rich domain 1 (CRD1) retained agonistic activity with physiological Fc gamma receptor crosslinking or as human immunoglobulin G2 isotype; agonistic activity decreased as epitopes drew closer to the membrane.
23293080MelanomaPromote immunityThe high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Finally, hFcgammaRI was capable of mediating antibody-induced immunotherapy of metastatic melanoma. Our results unravel novel capabilities of human FcgammaRI that confirm the role of high-affinity IgG receptors in vivo.
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCGR1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCGR1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4660.247
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8540.385
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1840.82
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5860.238
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4470.739
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.770.668
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0150.975
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2180.864
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2660.848
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9330.589
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9670.726
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3920.104
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCGR1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCGR1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCGR1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCGR1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCGR1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCGR1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCGR1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCGR1A
NameFc fragment of IgG, high affinity Ia, receptor (CD64)
Aliases CD64; CD64A; Fc fragment of IgG, high affinity Ia, receptor for (CD64); FCRI; Fc gamma receptor; Fc-gamma RI ......
Chromosomal Location1q21.2-q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCGR1A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FCGR1A.
ID Name Drug Type Targets #Targets
DB00002CetuximabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12
DB00005EtanerceptBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14
DB00028Immune Globulin HumanBiotechC3, C4A, C4B, C5, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR2C, FCGR3A, ......11
DB00051AdalimumabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00054AbciximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14
DB00056Gemtuzumab ozogamicinBiotechC1QA, C1QB, C1QC, C1R, C1S, CD33, FCGR1A, FCGR2A, FCGR2B, FCGR2C, ......12
DB00072TrastuzumabBiotechC1QA, C1QB, C1QC, C1R, C1S, EGFR, ERBB2, FCGR1A, FCGR2A, FCGR2B, F ......13
DB00073RituximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00074BasiliximabBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......13
DB00075MuromonabBiotechC1QA, C1QB, C1QC, C1R, C1S, CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2 ......15
DB00078Ibritumomab tiuxetanBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......12
DB00081TositumomabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB00087AlemtuzumabBiotechC1QA, C1QB, C1QC, C1R, CD52, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3 ......11
DB00092AlefaceptBiotechC1QA, C1QB, C1QC, C1R, CD2, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......11
DB00095EfalizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB00108NatalizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......12
DB00110PalivizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......10
DB00111DaclizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......12
DB00112BevacizumabBiotechC1QA, C1QB, C1QC, C1R, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A, FCG ......11
DB00707Porfimer sodiumSmall MoleculeFCGR1A, LDLR2
DB00992Methyl aminolevulinateSmall MoleculeFCGR1A1
DB06607CatumaxomabBiotechCD3E, EPCAM, FCGR1A, FCGR2A, FCGR3A, FCGR3B6
DB11767SarilumabBiotechFCGR1A, FCGR2A, FCGR2B, FCGR3A, FCGR3B, IL6R6